Nouveau Monde Graphite 주식 (NYSE: NMG)

Nouveau Monde Graphite (NYSE:NMG) 주식

Nouveau Monde Graphite

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.

NYSE

Equities

Markets

ETFs

ADRT

ARGT

BSAC

DFEN

DXYZ

GOLD

JCPB

NUSI

UPRO

XPER

뉴욕 증권 거래소(NYSE)의 여러 주식들은 기술적 문제로 인해 월요일 동부 표준시 오전 9시 40분 이후 갑자기 거래가 중단되었다. 이번 예상치 못한 거래 중단은 일반적으로 단일 주식의 과도한 변동성을 억제하는 데 사용되는 &#34;상향 한도(Limit Up)/하향 한도(Limit Down)&#34; 코드로 분류된 기술적 문제로 인해 촉발되었다.

버크셔 해서웨이, 치폴레 등 뉴욕 증권 거래소 기술적 문제로 일시 거래 중단 발생

Nouveau Monde Graphite Inc. Common Shares

Nouveau Monde Graphite Inc

NeoMagic Corp

NATION GROUP THAILAND PCL by NATION GROUP THAILAND PUB CO LTD.

Nano Magic Inc

<ul>
<li>On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)</li>
<li>U.S. FDA BLA submission for accelerated approval planned for 2H 2025</li>
</ul>
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).
"We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of 431 participants. Complete enrollment represents another key milestone on the path to potential approval of the first B cell modulator targeting both BAFF and APRIL for IgAN," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "We anticipate the 36-week primary efficacy endpoint data from the trial this quarter, which supports our planned Biologics License Application for an accelerated approval to the U.S. FDA in the second half of 2025. ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized kidney function through 96 weeks, positioning atacicept as a potential best-in-class IgAN therapy. Pending the submission and thorough FDA review of the BLA, we would look forward to a potential PDUFA date and commercial launch in 2026."
The ORIGIN 3 trial (NCT04716231) is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression. Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.
The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants. The key secondary efficacy endpoint is change in kidney function as measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.

Biotech

News

General

VERA

Vera Therapeutics Announces Full Enrollment In ORIGIN Phase 3 Trial For Atacicept In IgAN

The American Association of Individual Investors (AAII) survey revealed that bearishness, at 61.9%, continued to outpace bullish and neutral sentiment this week, marking a week-over-week rise in pessimism.
What Happened: The most recent results from the AAII Sentiment Survey, which tracks investor sentiment weekly from Thursday to Wednesday, revealed an increase in pessimism. Specifically, the proportion of individual investors expressing a bearish outlook on the stock market&#8217;s short-term trajectory surged by almost 10%, climbing from 52.2% to 61.9%.
This rise in the bearish sentiment marked a 16-year high from March 2009, as highlighted by Kevin Gordon, the director and senior investment strategist at Charles Schwab &amp; Co., in an X-post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">AAII bears highest since March 2009 <a href="https://t.co/OYzAj9O9yP">pic.twitter.com/OYzAj9O9yP</a>
&mdash; Kevin Gordon (@KevRGordon) <a href="https://twitter.com/KevRGordon/status/1907751165854429362?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bearish sentiment has now persisted above the 50% level for six consecutive weeks. This prolonged period of pessimism follows last week&#8217;s occurrence, which was the <a href="https://www.benzinga.com/markets/futures/25/03/44534664/bearish-sentiment-mirrors-35-year-old-pattern-hovering-over-50-for-5-weeks-expert-cites-incredible-buying-opportunities-from-past">first five-week stretch</a> of such elevated bearishness since similar patterns emerged in October 1990 and 2022. 
The historical average of bearish sentiments stood at 31%, which was half of the current pessimism among the participants of the AAII survey.
The bullish sentiment for the week stood at 21.8%, down from 27.4% last week, whereas the neutral sentiment shrank from 20.4% to 16.3% this week.
See Also: <a href="https://www.benzinga.com/25/04/44622754/tariffs-are-most-expensive-and-masochistic-could-cost-30-trillion-to-the-economy-erasing-300k-per-family-explains-former-treasury-secretary-larry-summers">Trump Tariffs Could Cost $30 Trillion Or About $300,000 Per Family, Says Former Treasury Secretary Larry Summers: &#8216;Most Expensive And Masochistic&#8217;</a>
Why It Matters: The worries about President Donald Trump's tariffs have worried the stock markets, increasing the pessimism among investors.
President Trump, citing a "large and persistent trade deficit," declared a <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted">trade emergency Wednesday</a>, utilizing a 1977 law to impose reciprocal tariffs.
The White House detailed the tariffs, emphasizing "Treat us like we treat you." While Canada and Mexico were exempt, China, Vietnam, Cambodia, and Sri Lanka faced the highest increases, leading gold prices to a record $3,167.71 and prompting a flight to safe-haven assets.
However, the respondents to AAII's special question this week about having gold in their portfolio were largely negative. The survey asked its participants if they held gold or other precious metals in their portfolio, either directly or through an ETF.
About 60.1% of respondents said "no," 18.5% responded "yes," and others admitted to holding both mining companies and precious metals in their portfolios.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Thursday. The SPY was down 3.30% to $545.87, while the QQQ declined 3.80% to $458.06, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Gold prices were lower by 0.17% at $3,127.80 after scaling a fresh record of $3,167.71 per ounce.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44623855/ray-dalio-warns-of-abrupt-unconventional-changes-in-markets-heres-how-the-tariff-machine-affects-currency-monetary-and-fiscal-policies">Ray Dalio Warns Of &#8216;Abrupt, Unconventional Changes&#8217; In Markets: Here&#8217;s How The &#8216;Tariff Machine&#8217; Affects Currency, Monetary And Fiscal Policies</a></li>
</ul>
Image via Shutterstock

Analyst Color

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Wall Street Worries Mount As Bearish Sentiment Hits Highest Level Since 2009 Amid Trump's Tariffs

<a href="https://www.globenewswire.com/Tracker?data=8ukNSezJvre1fdrHP-8DOmIkbv5HMNurS_7vKaN-s7OTkx5wkhgCIdWORIDuwL6k0fsV7ZYJyuoSB7LAf-eibvPiiFfPn_dKBraV3_5rYx0=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group,&nbsp;today announced that it is being forced to sell its Bitcoin Treasury after having been blocked from selling shares or raising funds, and specifically from using investor funds to buy Bitcoin by the United States District Court Southern District of New York (SDNY).
As previously reported by the Company, on October 30, 2024 Genius initiated arbitration procedures to terminate its Asset Purchase Agreement (APA) with Fatbrain AI (LZGI), and on December 17, 2024 both parties agreed to a preliminary injunction on the Company's shares related to the APA (Case 1:24-cv-08468-MKV).
This took place after LZGI's shareholders filed a lawsuit against LZGI and its officers, Michael Moe and Peter Ritz alleging a history of fraud, including in their actions related to the APA (Case 1:24-cv-07551), and after the SEC filed shareholder fraud allegations for defrauding LZGI shareholders amongst others (Case 2:24-cv-00918).
Further to these filings, on February 14, 2025, Moe and Ritz filed for a Temporary Restraining Order (TRO) and Preliminary Injunction (PI) to prevent Genius from selling any shares, or raising any funds, including through the use of its $150m ATM funding, and specifically from buying Bitcoin. On the same day, the TRO was granted, and on March 13, 2025, the SDNY granted the PI.
Over the last six weeks, Genius has filed multiple letters and motions to the court explaining that the TRO and PI did not maintain the status quo pending arbitration, that they were based on false statements designed to defraud the court, and the intent of the filing of the TRO and PI was to extort further money from Genius.
Genius also filed with the court a transcript of a meeting with Ritz and Genius executives recorded in New York on February 27, 2025 in which Ritz explained in detail how he has weaponized the TRO and PI process in order to extort millions more out of Genius to aid his personal scheme to defraud his LZGI shareholders.
This transcript has also been filed by LZGI's shareholders in their derivative case against LZGI, Moe and Ritz in the United States District Court Southern District of Florida (Case 1:25-cv-21062-JEM). Genius, which was initially named in both LZGI shareholder lawsuits has subsequently been voluntarily dismissed from both.
To date, the PI has remained in effect. As a result, Genius has had its financing and Bitcoin Treasury activities blocked by court order for the last six weeks, in direct opposition to the wishes, consent and approvals of the Company's Board and shareholders. As the injunction also prevents Genius from issuing share compensation to employees as part of their long standing employment agreements, Genius is in the unusual position of being legally compelled by a US court to directly break Singapore law.
As a result of the PI, which legally blocks Genius from being able to fund its operations, Genius is currently taking the following actions:
<ul>
<li>Pursuing an appeal with the second circuit: The Company filed an emergency motion to vacate the PI and for an immediate administrative stay with the United States Court of Appeals for the Second Circuit on March 19, 2025, and is awaiting the outcome of the appeal. &nbsp;</li>
<li>Restructuring operations: With the legal block on the Company's ability to issue shares or raise funds, the Company is taking steps to downsize its operations, including closing various divisions and cancelling all event sponsorships, marketing activity, and investing activities until such time that the Company is legally able to resume its growth plans. &nbsp;</li>
<li>Downsize its Bitcoin Treasury: By blocking all share sales and all receipt of investor funds, the Court is forcing the Company to sell its Bitcoin Treasury to fund its operations. Genius is taking all necessary measures to minimize Bitcoin sales but anticipates that it will need to downsize its Bitcoin Treasury in the coming months in the event the PI remains in place. As at today's date, the Company has had to reduce its Bitcoin holdings from 440 Bitcoin to 430 Bitcoin. &nbsp;</li>
<li>Retaining its public listed status: The LZGI complaints against Ritz and Moe details an ongoing history of defrauding investors by diverting funds for personal gain and pushing the companies they target into insolvency and closure. The SEC complaint details a pattern of defrauding investors and short selling companies including LZGI. Genius has provided evidence to the court that this same modus operandi is now being applied to Genius. The Company is committed to fighting against this fraudulent behaviour using all legal means available. &nbsp;</li>
</ul>

Legal

Genius Group Announces That It Is Being Forced To Sell Its Bitcoin Treasury After Having Been Blocked From Selling Shares Or Raising Funds, And Specifically From Using Investor Funds To Buy Bitcoin By The United States District Court Southern District Of New York

<ul>
<li>Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally</li>
<li>TMJ causes pain and stiffness in the jaw, making it difficult to chew</li>
<li>TMJ osteoarthritis currently has no long-term effective treatments</li>
</ul>
Ness-Ziona, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>, the "Company" or "Enlivex"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra&#x2122; for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis.
The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery at Sheba Medical Center. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek.
Dr. Einat Galamidi, CMO of Enlivex, commented, "This study will provide a preliminary evaluation of the safety and potential effect of AllocetraTM for the treatment of TMJ osteoarthritis, which affects a joint that is critical for daily function. We are pleased to report that the injection of AllocteraTM into the first patient's TMJ was successfully completed with no complications."
The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for TMJ osteoarthritis. The trial's primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and efficacy endpoints will assess changes from baseline in TMJ pain, joint functionality, and other disease parameters for up to 12 months following administration of Allocetra&#x2122;.

ENLV

Enlivex Doses First Patient In Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis

CNTM

ConnectM Technology Solutions Board To Evaluate $46.5M Buy-Out Offer

<h3>Gainers</h3>
<ul>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock rose 15.9% to $0.02 during Thursday's pre-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock increased by 12.84% to $0.52. The market value of their outstanding shares is at $5.1 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares increased by 11.62% to $1.44. The company's market cap stands at $27.6 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock increased by 9.25% to $1.18. The company's market cap stands at $10.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) shares decreased by 32.6% to $17.01 during Thursday's pre-market session. The market value of their outstanding shares is at $410.4 million. </li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares declined by 29.42% to $176.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Mister Car Wash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NASDAQ">MCW</a>) shares declined by 23.08% to $6.2. The company's market cap stands at $2.0 billion. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares decreased by 20.81% to $1.37. The market value of their outstanding shares is at $7.4 million. </li>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) stock decreased by 17.44% to $1.8. The company's market cap stands at $52.0 million. </li>
<li>Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) stock fell 16.38% to $28.2. The company's market cap stands at $3.5 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CJET

LEGH

TCTM

10 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) stock increased by 17.6% to $0.92 during Thursday's pre-market session. The market value of their outstanding shares is at $34.9 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock moved upwards by 12.84% to $0.64. The market value of their outstanding shares is at $9.6 million. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares increased by 7.97% to $0.81. The market value of their outstanding shares is at $23.5 million. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares rose 7.01% to $1.07. The company's market cap stands at $27.2 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares rose 6.1% to $3.13. The company's market cap stands at $40.2 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>NL Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NL#NYSE">NL</a>) shares moved upwards by 6.09% to $8.35. The market value of their outstanding shares is at $407.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) stock decreased by 32.5% to $9.0 during Thursday's pre-market session. The company's market cap stands at $859.5 million. </li>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) stock decreased by 24.71% to $21.0. The company's market cap stands at $277.1 million. The company's, Q2 earnings came out yesterday. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock fell 23.85% to $4.79. The company's market cap stands at $2.8 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) shares fell 14.26% to $4.45. The market value of their outstanding shares is at $55.6 million. </li>
<li>Covenant Logistics Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVLG#NYSE">CVLG</a>) stock fell 12.59% to $20.21. The market value of their outstanding shares is at $532.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

BIYA

CVLG

EHGO

FTCI

PMEC

11 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Powell Max (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) shares moved upwards by 54.9% to $0.69 during Thursday's pre-market session. The market value of their outstanding shares is at $10.1 million. </li>
<li>SHF Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) stock rose 31.52% to $4.13. The company's market cap stands at $11.5 million. </li>
<li>Old Point Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPOF#NASDAQ">OPOF</a>) stock rose 17.18% to $35.05. The company's market cap stands at $177.9 million. </li>
<li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNGD#NYSE">FNGD</a>) shares increased by 13.91% to $19.5. </li>
<li>Atlantic American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAME#NASDAQ">AAME</a>) shares moved upwards by 6.32% to $1.68. The market value of their outstanding shares is at $34.2 million. </li>
<li>AtlasClear Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#AMEX">ATCH</a>) shares increased by 6.15% to $0.59. The market value of their outstanding shares is at $3.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) stock decreased by 47.8% to $5.01 during Thursday's pre-market session. The company's market cap stands at $123.8 million. </li>
<li>Ponce Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDLB#NASDAQ">PDLB</a>) shares declined by 37.62% to $8.01. The company's market cap stands at $181.5 million. </li>
<li>RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) stock fell 32.03% to $11.25. The market value of their outstanding shares is at $199.4 million. </li>
<li>CNB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) shares decreased by 28.88% to $16.01. The company's market cap stands at $335.8 million. </li>
<li>Penns Woods Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWOD#NASDAQ">PWOD</a>) shares fell 21.98% to $22.01. The company's market cap stands at $167.5 million. </li>
<li>PCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCB#NASDAQ">PCB</a>) shares decreased by 19.13% to $15.01. The market value of their outstanding shares is at $215.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAME

ATCH

CCNE

FNGD

FRST

OPOF

PDLB

PMAX

PWOD

SHF Holdings, Inc. - Class A Common Stock

SHFS

12 Financials Stocks Moving In Thursday's Pre-Market Session

<ul>
<li>Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025</li>
<li>Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldeyra.com%2F&amp;esheet=54232964&amp;newsitemid=20250403220331&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=231423ca5b7730a157e413b7ea8d690e">Aldeyra Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were identified, the FDA stated in the letter that the NDA "failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes" and that "at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye" should be conducted. The letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms.

ALDX

Aldeyra Therapeutics Receives Complete Response Letter From The U.S. FDA For The Reproxalap New Drug Application For The Treatment Of Signs And Symptoms Of Dry Eye Disease

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares moved upwards by 179.6% to $0.63 during Thursday's pre-market session. The company's market cap stands at $4.5 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock increased by 122.46% to $3.07. The company's market cap stands at $4.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 62.76% to $5.29. The company's market cap stands at $3.2 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock moved upwards by 44.95% to $2.13. The company's market cap stands at $41.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock increased by 21.08% to $0.36. The company's market cap stands at $3.0 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 13.64% to $0.15. The market value of their outstanding shares is at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) stock fell 29.2% to $18.49 during Thursday's pre-market session. The market value of their outstanding shares is at $748.7 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares fell 24.18% to $0.67. The market value of their outstanding shares is at $10.5 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) stock fell 23.01% to $4.1. The market value of their outstanding shares is at $244.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 22.95% to $0.23. The company's market cap stands at $4.6 million. </li>
<li>ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) stock fell 20.11% to $4.61. The market value of their outstanding shares is at $176.0 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 19.56% to $1.81. The market value of their outstanding shares is at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

BIAF

GNPX

ITOS

OSRH

PTIX

QNRX

RXST

SBFM

TIVC

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

ATLANTA and SUNNYVALE, Calif., April 3, 2025 /PRNewswire/ -- Google Cloud today announced an expanded multi-year partnership with Papa Johns to revolutionize the pizza maker's ordering and delivery experience using the power of artificial intelligence (AI). Through the partnership Papa Johns has created an innovation team, named PJX, that will leverage Google Cloud's AI, data analytics and machine learning (ML) capabilities to provide a more frictionless and consistent experience for customers both inside its restaurants and throughout its digital channels.
Through its partnership with Google Cloud, Papa Johns expects to drive success through increased order frequency, higher-value orders, reduced customer service costs, improved customer satisfaction (via a chatbot powered by Google Cloud's technology) – and ultimately, more joyful pizza experiences.
"At Papa Johns, our aspiration is to be the best pizza makers in the business. Being the best means we are crafting great pizza and providing every single customer a superior experience along every part of their journey – from ordering, to delivery, to our loyalty program," said Todd Penegor, President and CEO, Papa Johns. "Our partnership with Google Cloud will enable us to take personalization to the next level. We're not just reacting to orders – we're anticipating our customers' needs and proactively providing tailored recommendations and offers. This isn't just about convenience; it's about creating a truly joyful and personalized pizza experience that builds lasting loyalty."

Contracts

GOOG

PZZA

Papa Johns And Google Cloud Enters Partnership To Deliver AI-Powered Pizza Experiences

Founder &amp; CEO of Professional Capital Management, <a href="https://www.benzinga.com/25/03/44433988/tether-is-now-too-big-to-fail-says-anthony-pompliano-citing-its-growing-role-in-us-treasury-markets">Anthony Pompliano</a> has praised the new tariffs introduced by President Donald Trump on Wednesday, arguing that they highlight the inefficiencies of traditional financial systems and bolster the case for decentralized finance solutions like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: Speaking on a <a href="https://x.com/APompliano/status/1907532904403489074">podcast</a>, Pompliano linked the tariffs to broader economic shifts, while the crypto market faced significant declines amid fears of a global trade war sparked by the new policy.
Pompliano emphasized that the tariffs underscore the vulnerabilities of centralized banking systems, which he claims have been weaponized against businesses for political reasons. 
He recounted the Trump family's experience with banks like Capital One, Chase, Bank of America and First Republic, which canceled their accounts during Donald Trump's presidency, a move he described as "political lawfare."
This experience, shared by Eric Trump on the same broadcast, drove the family to embrace cryptocurrency. 
"I realized the power that these banks had, and I realized how they were exerting that power, and they were canceling businesses all over our country," Eric Trump said, explaining his shift toward crypto.
The tariffs, unveiled by Trump in a <a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">White House Rose Garden ceremony</a>, impose a "reciprocal tariff rate" set at 50% of what trading partners charge the U.S., targeting countries like Vietnam, Cambodia and Sri Lanka with the steepest increases, while sparing Canada and Mexico.
Trump called the move "our Declaration of Economic Independence," stating, "April 2nd will forever be remembered as the day American industry was reborn."
However, the announcement triggered a sharp decline in crypto markets on Wednesday, with Bitcoin plunging to $82,400 levels from its all-time high of $108,786.
Major altcoins like Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) also traded down 8-10% after the announcement.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44613293/avax-to-outperform-bitcoin-ethereum-reaching-250-by-2029-standard-chartered">AVAX To Outperform Bitcoin, Ethereum, Reaching $250 By 2029: Standard Chartered</a>
Why It Matters: Despite the market downturn, Pompliano sees the tariffs as a validation of crypto's potential to address systemic financial issues.
He argued that blockchain technology offers a more efficient alternative to traditional banking, which he criticized for its outdated practices. 
"There's not a single thing that those banks do that can't be done better, cheaper, more efficiently, faster on blockchain," Pompliano stated, highlighting Bitcoin's role as a store of value and a hedge against real estate.
The broader economic context also includes concerns about the rising costs of materials for AI data centers, as noted by Tory Green, CEO of io.net, a global GPU-power aggregator. 
Green dismissed concerns about rising costs for AI infrastructure caused by tariffs. Instead, he argued that the U.S. should prioritize tapping into idle computing resources rather than building new data centers.
"We're significantly underutilizing the resources we already have," Green said. "The real problem isn't cost—it's inefficiency. We don't need more concrete; we need better connectivity."
Green pointed to benchmarks showing that idle computers still consume up to 60% of the energy used by public cloud systems, and cited a recent MIT Technology Review report showing that 80% of China's AI data centers currently sit idle.
Meanwhile, the Trump family has deepened its involvement in the crypto space, with Eric Trump and Donald Trump Jr. <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44591699/eric-trump-hails-bitcoin-as-one-of-the-greatest-stores-of-value">announcing their investment in a Bitcoin mining company</a>, American Bitcoin, which aims to merge with Trumps American Data Centers to become the world's largest crypto miner and establish its own Bitcoin reserve.
Eric Trump also highlighted the success of their venture, World Liberty Financial, which recently launched a stablecoin, reflecting their belief in crypto's transformative <a href="https://www.benzinga.com/markets/equities/25/04/44620686/sp-500-nasdaq-futures-plunge-over-3-as-trumps-reciprocal-tariff-plan-hits-market-confidence">potential for the U.S. economy.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44613226/bitcoin-braces-for-trump-tariff-announcement-short-term-optimism-has-the-upper-hand-expert">Bitcoin Braces For Trump Tariff Announcement: &#8216;Short-Term Optimism&#8217; Has The Upper Hand, Experts Say</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$DOGE

$SOL

Anthony Pompliano Praises Trump's Tariffs As Catalyst For Crypto Innovation

OTRK

Ontrak Obtains Medicaid Provider Designation In Two New States, Enhancing Direct Service Delivery Capabilities

Flamingo-01 Progress to Date &amp; Future Plans
The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A&#x2A;02 and non-HLA-A&#x2A;02 arms. The non-HLA-A&#x2A;02 arm was expanded to 250 patients in 2024 with approval from both EU and US regulators. With the new preliminary positive immune response data in these patients, further changes are being considered, including the potential to transform the non-HLA-A&#x2A;02 open label third arm into effectively a second Phase III trial which could lead to multiple pathways for marketing approval of GLSI-100 and a larger market potential.
In Q1 2025, the Company achieved its highest screening rate of over 150 patients per quarter or the equivalent of 600 patients per year in 40 US sites and 77 EU sites for a total of 117 active sites. In addition, 30 sites in the EU are planned to be activated in 2025 with the potential for another 10 sites to be approved and added in additional EU countries, bringing the total potential sites to over 150 sites globally. Once these sites are activated, the Company is considering a strategy to continue enrolling in both of the HLA-A&#x2A;02 and non-HLA-A&#x2A;02 arms until an interim analysis is conducted and the appropriate size of each arm can be further assessed.
US Clinical Sites Participating in Flamingo-01
Approximately 40 US clinical sites with 134 locations, including sites in the US Oncology/Sarah Cannon network, are currently recruiting patients and are listed below and at <a href="https://www.globenewswire.com/Tracker?data=ZOOE7GcmuHn1-bvAvPjkKuZlaOKOTR0K54sZEZdnf8W9KnYT3iBgx9piwuTyHo4_4Z6jbYFzi3Y_Y6u0dNuwX6EZua90m9hSMaoROu4rUNDS1R-NLEPSZaSsp-sH0kKYj9m5s-ECPtZUEYU-fa50l0dGvRMf8SvHOWIlFgm0Ptk=">www.clinicaltrials.gov/study/NCT05232916</a>. Many of the sites are prominent teaching hospitals, including Yale, Johns Hopkins, Harvard, Huntsman, Moffitt, Stanford, UCSF, UCLA, UCSD, UT Southwestern, UT San Antonio, Columbia, Northwestern, Washington University, Thomas Jefferson, Stony Brook, and Baylor, which is the lead site.
European Clinical Sites and Networks Participating in Flamingo-01
In early 2024, the expansion of Flamingo-01 into 5 EU countries was approved by European regulators. Since that time, 77 clinical trial sites have been activated, and study recruitment is well underway in Spain (29), France (17), Germany (18), Italy (9), and Poland (4).
European academic networks in each country are participating in Flamingo-01 and are listed below. These networks represent the largest oncology focused hospitals and centers in Europe, where breast cancer leaders work in a collaborative manner to help advance promising therapies. The networks hold annual scientific meetings where Flamingo-01 has been introduced and where the Company has presented in the past.
GEICAM is the leading group in breast cancer research in Spain and currently consists of more than 900 experts, who work in more than 200 centers throughout Spain. Since its establishment in 1995, GEICAM has carried out more than one hundred studies in which more than 66,000 women and men have participated.
UCGB or Unicancer is the federation of French comprehensive cancer centers, a major player in cancer research and a network of 20 private, non-profit healthcare centers specialized in oncology, brought together in a health cooperation group.
GBG Forschungs GmbH is one of the world's leading breast cancer research institutes that works together with the academic study group German Breast Group (GBG). With more than 67,000 study participants and 3,500 new patients per year, GBG is the largest breast cancer study group in Germany, consisting of more than 1,000 doctors in over 800 centers.&nbsp;
GIM (Gruppo Italiano Mammella) is a cooperative Italian network for breast cancer research and therapy.&nbsp;GIM brings together over 150 participating centers and around 500 investigators.

GLSI

Greenwich Lifesciences Provides Update On Its Phase III Clinical Trial, Flamingo-01, Which Is Evaluating GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences

Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>), a leading global media measurement and optimization platform, today announced the expansion of its partnership with Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>), a community platform powered by conversation and authentic human connection. Global advertisers can now access expanded measurement capabilities across Reddit, including Viewability and Invalid Traffic Measurement, as part of IAS's Total Media Quality for Reddit.
With IAS's Total Media Quality for Reddit, advertisers can remain confident that their media buys are reaching real users across more than 100,000 authentic interest-based, intent-driven communities on the platform.
"IAS's Total Media Quality for Reddit provides advertisers with third-party campaign insights backed by trusted and transparent metrics to help brands safeguard and scale across Reddit's unique communities and conversations," said Lisa Utzschneider, CEO of IAS. "Reddit continues to provide advertisers with a platform to reach highly engaged communities, and we are excited to expand our solutions to give Reddit advertisers actionable data to better inform media buys on the platform."
With Total Media Quality for Reddit, IAS will provide advertisers with:
<ul>
<li>Greater Transparency:&nbsp;Advertisers can validate their content adjacency with trusted third-party analysis aligned to industry frameworks, and validate that they are engaging with real users and maximizing campaign spend.</li>
<li>Comprehensive Reporting:&nbsp;Advertisers can leverage IAS Signal, IAS's unified reporting platform, for industry leading Viewability, Invalid Traffic, and Brand Safety and Suitability Measurement with content-level insights that enable advertisers to stay informed and take action.</li>
<li>Best-in-class Technology:&nbsp;Total Media Quality for Reddit is powered by IAS's AI-driven Multimedia Technology, which enables advertisers to accurately classify content at scale through frame-by-frame analysis, combining image, audio, and text signals.</li>
<li>Global Coverage:&nbsp;IAS supports measurement across web and in-app, video, and display campaigns for Reddit's Feed, Conversation, and Takeover placements.</li>
</ul>
"As Reddit's advertising business continues to grow, this expanded partnership with IAS reinforces our commitment to providing advertisers with third-party reporting and deeper insight into their presence on the platform," said Jim Squires, EVP of Business Marketing and Growth at Reddit. "IAS's Total Media Quality for Reddit is an added layer of information that gives brands even greater clarity and confidence in the value of being part of conversations that matter to their business."

RDDT

Integral Ad Science Announces Expansion Of Its Partnership With Reddit

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)&nbsp;plans to release Qwen 3, an upgraded version of its flagship <a target="_blank" href="https://www.benzinga.com/topic/alibaba" rel="noreferrer noopener">AI model, by April</a>.
China&#8217;s tech leaders have flooded the market with affordable AI services since a domestic AI startup, DeepSeek,&nbsp;showcased a robust model that it said cost just several million dollars to build, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-01/alibaba-preparing-for-flagship-ai-model-release-as-soon-as-april?sref=TBDibEcD" rel="noreferrer noopener">reports</a>.&nbsp;&nbsp;
OpenAI, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Anthropic have similarly released new models.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/03/44561764/alibabas-march-expo-sparks-27-jump-in-us-small-business-orders" rel="noreferrer noopener">Alibaba&#8217;s March Expo Sparks 27% Jump In US Small Business Orders</a>
The wave of new Asian models is questioning the sustainability of the high-end U.S. offerings from &nbsp;OpenAI,&nbsp;Google, and&nbsp;Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Last week, Alibaba launched a new model in its Qwen 2.5 series that can process text, pictures, audio, and video and run directly on mobile phones and laptops. It showcased a new version of the AI assistant Quark app in March.
After grappling with <a target="_blank" href="https://www.benzinga.com/25/03/44536478/alibabas-ai-driven-rally-signals-china-techs-revival-report" rel="noreferrer noopener">domestic regulatory crackdowns</a>, leadership reshuffles, and collapsing market confidence, Alibaba stock noted a turnaround. A rallying call from co-founder Jack Ma in late 2023 helped ignite a turnaround that has pushed the company&#8217;s U.S.-listed shares up 56% year-to-date, adding more than $100 billion to its valuation.
Under the leadership of Eddie Wu and Joe Tsai, the company has since leaned into artificial intelligence.
The return of Alibaba co-founder Jack Ma to public view, particularly during a meeting with President Xi Jinping in February, signaled improved relations between Alibaba and China&#8217;s leadership.
Dan Ives&nbsp;of Wedbush Securities called Alibaba the &#8220;best way to play China tech,&#8221; citing its strong positioning in AI and cloud.
Price Action: BABA stock is down 3.15% at $125.70 premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/04/44582215/chinas-xpeng-clocks-record-q1-ev-sales-deliveries-surge-3-6x" target="_blank" rel="noreferrer noopener">China&#8217;s XPeng Clocks Record Q1 EV Sales, Deliveries Surge 3.6X</a></li>
</ul>
Photo by jackpress via Shutterstock

Asia

Tech

Media

BABA

GOOGL

MSFT

Alibaba Steps Up AI Game With Qwen 3, Challenging DeepSeek's Low-Cost AI Success

During the last three months, 20 analysts shared their evaluations of Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $91.5, a high estimate of $110.00, and a low estimate of $70.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.27%. 
<img src="https://www.benzinga.com/files/images/story/2025/1743681657_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$81.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$93.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Elizabeth Suzuki</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jonathan Matuszewski</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Best Buy Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Best Buy Co's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Best Buy Co's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>Get to Know Best Buy Co Better</h2>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Key Indicators: Best Buy Co's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Best Buy Co faced challenges, resulting in a decline of approximately -4.77% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Best Buy Co's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.84%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Best Buy Co's ROE stands out, surpassing industry averages. With an impressive ROE of 3.97%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Best Buy Co's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.74%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.44, Best Buy Co faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 20 Analyst Projections For Best Buy Co

Throughout the last three months, 25 analysts have evaluated Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Apple, revealing an average target of $259.2, a high estimate of $325.00, and a low estimate of $183.00. This current average has increased by 0.18% from the previous average price target of $258.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1743681651_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Apple. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$300.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$263.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$252.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$197.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Edison Lee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Underperform</td>
<td>$202.33</td>
<td>$200.75</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$294.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$262.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$253.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$280.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$183.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Kyle Mcnealy</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$200.75</td>
<td>$211.84</td>
</tr>
<tr>
<td>Ananda Baruah</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$230.00</td>
<td>-</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Craig Moffett</td>
<td>MoffettNathanson</td>
<td>Lowers</td>
<td>Sell</td>
<td>$188.00</td>
<td>$202.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apple. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apple compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Apple's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Apple's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apple analyst ratings.</a>
<h2>About Apple</h2>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
<h3>Apple's Economic Impact: An Analysis</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Apple's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.95%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 29.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apple's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 58.74%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 10.25%, the company showcases effective utilization of assets.
Debt Management: Apple's debt-to-equity ratio stands notably higher than the industry average, reaching 1.45. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

Forecasting The Future: 25 Analyst Projections For Apple

Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Arcutis Biotherapeutics and provided 12-month price targets. The average target is $19.11, accompanied by a high estimate of $21.00 and a low estimate of $15.00. Surpassing the previous average price target of $18.33, the current average has increased by 4.26%.
<img src="https://www.benzinga.com/files/images/story/2025/1743681644_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Arcutis Biotherapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kambiz Yazdi</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Arcutis Biotherapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcutis Biotherapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Arcutis Biotherapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Arcutis Biotherapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ARQT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Arcutis Biotherapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Arcutis Biotherapeutics Better</h2>
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
<h3>Unraveling the Financial Story of Arcutis Biotherapeutics</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Arcutis Biotherapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 427.58%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Arcutis Biotherapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -15.12% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Arcutis Biotherapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.87% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Arcutis Biotherapeutics's ROA excels beyond industry benchmarks, reaching -2.74%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.7.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARQT

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews

In the preceding three months, 9 analysts have released ratings for TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated TJX Companies and provided 12-month price targets. The average target is $139.78, accompanied by a high estimate of $151.00 and a low estimate of $120.00. This upward trend is apparent, with the current average reflecting a 3.29% increase from the previous average price target of $135.33.
<img src="https://www.benzinga.com/files/images/story/2025/1743681632_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of TJX Companies among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$137.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$151.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to TJX Companies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TJX Companies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of TJX Companies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TJX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TJX Companies analyst ratings.</a>
<h2>Discovering TJX Companies: A Closer Look</h2>
TJX Companies is the leading off-price retailer of apparel, accessories, and home merchandise in the United States. The firm leverages its more than 20,000 global vendor relationships to procure and sell brand-name merchandise at prices 20%-60% cheaper than conventional retail channels. TJX opportunistically purchases excess inventory that stems from manufacturing overruns and retail closeout sales. The retailer disperses its vast and disparate merchandise across its 5,000 global stores, creating a treasure-hunt shopping experience for consumers. Over three quarters of TJX's sales are derived from the United States, primarily via the T.J. Maxx, Marshalls, and HomeGoods banners. About 10% of sales are from Canada and 12% from Europe and Australia.
<h3>Unraveling the Financial Story of TJX Companies</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining TJX Companies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.26% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: TJX Companies's net margin excels beyond industry benchmarks, reaching 8.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): TJX Companies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 16.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): TJX Companies's ROA stands out, surpassing industry averages. With an impressive ROA of 4.36%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.52, TJX Companies faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Have This To Say About TJX Companies

Press Releases

The Atikamekw First Nation of Manawan and NMG Sign an Impact Benefit Agreement for the Matawinie Mining Project

NMG Appoints Chantal Sorel to Its Board of Directors

Canada Growth Fund announces first transaction in critical minerals sector with investment in Quebec-based Nouveau Monde Graphite

NMG Pays Accrued Interests

NMG Announces Uplisting to the Toronto Stock Exchange

Small Cap

Mason Resources Acquires Additional Securities of NorthX Nickel Corp.

NMG to Present at BMO's Global Metals, Mining and Critical Minerals Conference

NMG Issues Updated Feasibility Study for its Integrated Phase-2 Ore-to-Active-Anode-Material Operations: the Matawinie Mine and the Bécancour Battery Material Plant

NMG Files 2024 Financial Reports and Provides an Update on its Roadmap to FID for the Integrated Phase-2 Matawinie Mine and Bécancour Battery Material Plant

Comments

Nouveau Monde Graphite

뉴스

파트너 / 기고자

벤징가 글로벌